Published within
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
New trial results suggest that Novartis' 400mg Prexige is superior to 200mg Celebrex at providing pain relief for osteoarthritis patients. However, further studies will be needed to consider like-for-like tests and cardiovascular side effects. The results of these will be critical to Prexige's positioning in the extremely competitive pain relief market.
Published By Datamonitor
|
04 Oct 2002 |
|
CommentWire
|
A meta-analysis of bisphosphonate studies found that the drugs can lower skeletal morbidity in patients with metastatic disease. With Novartis' [NVS] Zometa recently gaining a sNDA for patients with bone metastases from advanced malignancies and this class of adjunct therapy becoming increasingly used, Zometa should be blockbuster by the end of 2003.
Published By Datamonitor
|
01 Sep 2003 |
|
CommentWire
|
Before the FDA asked for additional clinical data, Novartis' [NVS] Prexige was set to be the sixth brand to enter the COX-II market, which already contains Pfizer's [PFE] Celebrex (celecoxib) and Merck's [MRK] Vioxx (rofecoxib). As one of the few potential blockbusters Novartis has in its pipeline, the drug's approval is extremely important for its continuing financial health.
Published By Datamonitor
|
14 Oct 2003 |
|
Expert View
|
Novartis has unveiled promising Phase II data for its once-daily bronchodilator, indacaterol (QAB-149). With a long duration of action, rapid onset of action and clean side effects profile, the drug could provide a new standard for bronchodilator therapy in patients with asthma and chronic obstructive pulmonary disease (COPD).
Published By Datamonitor
|
09 Jun 2005 |
|
CommentWire
|
Following its EU approval, Novartis will look to launch Prexige in the EU during 2007. Despite safety fears over the COX-2 class, there will be a market for Prexige in osteoarthritis as the drug enjoys a similar CV safety profile to Pfizer's Celebrex. Prexige is not expected to reach blockbuster status, but will compete well against Celebrex and Merck's Arcoxia in the five major EU markets.
Published By Datamonitor
|
09 Nov 2006 |
|
CommentWire
|
Independent Swiss pharmaceutical company Basilea has announced that its dermatology drug alitretinoin has shown positive results in a second phase III clinical trial for the treatment of severe chronic hand dermatitis. Based on these results, alitretinoin could fill an important unmet need for a safer therapy in this indication.
Published By Datamonitor
|
27 Apr 2007 |
|
CommentWire
|
The latest Phase III study results for Actemra confirm previous findings that the drug is a safe and effective biologic therapy for rheumatoid arthritis sufferers. In particular, Actemra will be a therapy for niche rheumatoid arthritis patients who do not adequately respond to anti-TNF or traditional disease-modifying drugs, further strengthening the immunology franchise of Roche and Chugai.
Published By Datamonitor
|
12 Jul 2007 |
|
CommentWire
|
Roche has agreed to acquire Piramed for $160m plus a milestone payment of $15m, due upon the start of Phase II clinical trials for the company's oncology program. Piramed's oncology and immunology and inflammation programs will add to Roche's already strong portfolio in these therapy areas and the move is in line with Roche's strategy of pursuing these two fastest growing therapeutic segments.
Published By Datamonitor
|
15 Apr 2008 |
|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.